Robert A. Gatenby
Applies evolutionary game theory to cancer treatment, dosing drugs to control rather than eradicate resistant clones.
Radiologist and mathematical oncologist who founded Moffitt's Integrated Mathematical Oncology department and ran the first adaptive-therapy trial (abiraterone in prostate cancer).
| Title | Journal | Year |
|---|---|---|
| Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer | Nature Communications | 2017 |
Pages like this
not linked directly; found by shared links- IdeaEvolution-guided 'adaptive therapy' dosing tested in randomised phase 2 trials
Shares Moffitt Cancer Center, Drug resistance (primary and acquired), Prostate cancer.
- TrialPROpel
Shares Abiraterone acetate, Prostate cancer.
- TrialMAGNITUDE
Shares Abiraterone acetate, Prostate cancer.
- IdeaAutonomous closed-loop adaptive therapy driven by blood tests and evolutionary models
Shares Moffitt Cancer Center, Drug resistance (primary and acquired), Prostate cancer.
- TrialCAPItello-281
Shares Abiraterone acetate, Prostate cancer.
- TrialPEACE-1
Shares Abiraterone acetate, Prostate cancer.
- IdeaSMART designs to test treatment strategies, not just single drugs
Shares Drug resistance (primary and acquired), Prostate cancer.
- PersonHoward I. Scher
Shares Abiraterone acetate, Prostate cancer.